An update on Zika vaccine developments

References

• Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev. 2016;29(3):487–524.
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Gubler DJ, Weaver SC, et al. Epidemic arboviral diseases: priorities for research and public health. Lancet Infect Dis. 2017;17(3):e101–e106.
   PubMedGoogle Scholar
• World Health Organization. WHO situation report Zika virus, microcephaly, Guillain-Barre syndrome. Geneva: WHO; 2017.
   Google Scholar
• Brasil P, Pereira JP Jr., Raja Gabaglia C, et al. Zika virus infection in pregnant women in Rio de Janeiro – preliminary report. N Engl J Med. 2016;375:2321–2334.
   PubMed Web of Science ®Google Scholar
• Brasil P, Pereira JP Jr., Moreira ME, et al. Zika virus infection in pregnant women in Rio de Janeiro. N Engl J Med. 2016;375(24):2321–2334.
   PubMed Web of Science ®Google Scholar
• Reynolds MR, Jones AM, Petersen EE, et al. Vital signs: update on Zika virus-associated birth defects and evaluation of all U.S. infants with congenital Zika virus exposure – U.S. Zika pregnancy registry, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(13):366–373.
   PubMed Web of Science ®Google Scholar
• Parra B, Lizarazo J, Jimenez-Arango JA, et al. Guillain-Barre syndrome associated with zika virus infection in Colombia. N Engl J Med. 2016;375(16):1513–1523.
   PubMed Web of Science ®Google Scholar
• Munoz LS, Barreras P, Pardo CA. Zika virus-associated neurological disease in the adult: Guillain-Barre syndrome, encephalitis, and myelitis. Semin Reprod Med. 2016;34(5):273–279.
   PubMed Web of Science ®Google Scholar
• Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387(10027):1531–1539.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Kochel TJ, Ewing D, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine. 2000;18(22):2426–2434.
   PubMed Web of Science ®Google Scholar
• Raviprakash K, Porter KR, Kochel TJ, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol. 2000;81(Pt 7):1659–1667.
   PubMed Web of Science ®Google Scholar
• Ocazionez Jimenez R, Lopes da Fonseca BA. Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice. Vaccine. 2000;19(6):648–654.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Supasa P, Wongwiwat W, et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus. Nat Immunol advance online publication. 2016;17:1102–1108.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO vaccine pipeline tracker. Geneva: WHO; 2017. Available from: http://www.who.int/immunization/research/vaccine_pipeline_tracker_spreadsheet/en/
   Google Scholar
• Vannice KS, Giersing BK, Kaslow DC, et al. Meeting report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency. Vaccine. 2016. [Epub ahead of print]
   Google Scholar
• Larocca RA, Abbink P, Peron JPS, et al. Vaccine protection against Zika virus from Brazil. Nature advance online publication. 2016;536:474–478.
   PubMed Web of Science ®Google Scholar
• Abbink P, Larocca RA, de la Barrera RA, et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science. 2016;353(6304):1129–1132.
   PubMed Web of Science ®Google Scholar
• Morrison C. DNA vaccines against Zika virus speed into clinical trials. Nat Rev Drug Discov. 2016;15(8):521–522.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396–1404.
   PubMed Web of Science ®Google Scholar
• Dowd KA, Ko SY, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science. 2016;354(6309):237–240.
   PubMed Web of Science ®Google Scholar
• Abbasi J. Zika vaccine enters clinical trials. Jama. 2016;316(24):1249.
   Google Scholar
• Richner JM, Himansu S, Dowd KA, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;169:176.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Pelc RS, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. 2017;543:248–251.
   PubMed Web of Science ®Google Scholar
• Shan C, Muruato AE, Nunes BTD, et al. A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nat Med. 2017;23(6):763–767.
   PubMed Web of Science ®Google Scholar
• Durbin AP, Kirkpatrick BD, Pierce KK, et al. A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis. 2013;207(6):957–965.
   PubMed Web of Science ®Google Scholar
• Durbin AP, McArthur JH, Marron JA, et al. rDEN2/4Delta30(ME), A live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum Vaccin. 2006;2(6):255–260.
   PubMed Web of Science ®Google Scholar
• Xie X, Yang Y, Muruato AE, et al. Understanding Zika virus stability and developing a chimeric vaccine through functional analysis. mBio. 2017;8(1):e02134-16.
   PubMed Web of Science ®Google Scholar
• Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine. 2010;28(3):632–649.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Tetravalent dengue vaccine: a review in the prevention of dengue disease. Drugs. 2016;76(13):1301–1312.
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Najburg V, et al. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine. 2010;28(41):6730–6739.
   PubMed Web of Science ®Google Scholar
• Brandler S, Ruffie C, Combredet C, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. 2013;31(36):3718–3725.
   PubMed Web of Science ®Google Scholar
• Coller BA, Clements D, Ogata S, et al. Clinical development of a recombinant subunit vaccine for dengue. In: Ed.^(Eds. American Society of Tropical Medicine and Hygiene 59th annual meeting. Atlanta, GA: American Society of Tropical Medicine and Hygiene; 2010. p. 248.
   Google Scholar
• Coller BA, Clements DE, Bett AJ, et al. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine. 2011;29:7267–7275.
   PubMed Web of Science ®Google Scholar
• Lieberman MM, Nerurkar VR, Luo H, et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Cvi. 2009;16(9):1332–1337.
   Web of Science ®Google Scholar
• Liu Y, Zhou J, Yu Z, et al. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties. BMC Microbiol. 2014;14:233.
   PubMedGoogle Scholar
• Suphatrakul A, Yasanga T, Keelapang P, et al. Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells. Vaccine. 2015;33(42):5613–5622.
   PubMed Web of Science ®Google Scholar
• Lim JK, Lee YS, Wilder-Smith A, et al. Points for consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative. Expert Rev Vaccines. 2016;15(4):529–538.
   PubMed Web of Science ®Google Scholar